Engineered Multi-Strain Yogurt Recruits Commensal Bacteroides to Subdue Inflammaging and Sleep Disturbances

News
#1

Yogurt
Yogurt2752Ă—1536 391 KB

Chronic functional constipation is far more than a localized gastrointestinal inconvenience; it represents a systemic pathophysiological disrupter intimately tied to anxiety and sleep architecture degradation via the bidirectional gut-brain axis. High-fat Western diets and modern processed foods continuously alter colonic mucus secretion and select for a dysbiotic microbiome, maintaining a state of persistent low-grade systemic inflammation. While conventional commercial yogurts rely on a rudimentary two-strain baseline of Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus, emerging clinical evidence demonstrates that escalating microbial complexity within the fermentative substrate can fundamentally reshape host physiology.

The core innovation centers on an engineered 10-strain bacterial consortium, designated K-10, constructed from indigenous lactic acid bacteria isolated from artisanal dairy fermentation ecosystems in Inner Mongolia and Tibet. By deploying this highly diversified multi-strain formulation, researchers successfully engineered a cross-feeding metabolic cascade that shifts host intestinal microecology away from inflammatory pathogens and toward complex carbohydrate degradation. Rather than acting as a transient probiotic vector, the K-10 intervention systematically enriched indigenous commensal Bacteroides populations—most notably Bacteroides uniformis—within the human gut.

Bacteroides species possess specialized Starch Utilization Systems (Sus-like gene clusters) that encode extracellular hydrolases capable of breaking down complex, recalcitrant dietary polysaccharides into fermentable monosaccharides. Predictive metabolic pathway analysis confirmed a substantial upregulation of carbohydrate-degrading glycoside hydrolases under the K-10 regimen. This enzymatic shift accelerated the conversion of monosaccharides into high concentrations of short-chain fatty acids (SCFAs), specifically acetate and butyrate.

The downstream repercussions of this microbial pivot extend well beyond the colon. The localized surge in SCFAs directly correlates with a profound down-regulation of circulating pro-inflammatory cytokines, reducing serum Tumor Necrosis Factor-alpha (TNF-alpha) by 34.2% and Interleukin-6 (IL-6) by 39.8%. Simultaneously, the treatment alleviated the mechanical distress of constipation, dropping average symptom scores below clinical thresholds into full remission. Most critically, these metabolic alterations resonated up the neuro-intestinal axis: serum levels of serotonin (5-HT) and dopamine experienced significant elevation, paired with a systemic drop in cortisol. This neuro-endocrine recalibration delivered tangible clinical benefits, significantly reducing sleep latency and breaking patient dependence on hypnotic sleep aids. The study reveals that broad-spectrum probiotic consortia can exploit cross-feeding networks to optimize the gut-brain axis, presenting a scalable strategy to counter the systemic inflammatory and psychological declines of aging.

Actionable Insights for Healthspan and Longevity

To optimize healthspan and target the systemic metrics of aging, individuals should look beyond standard commercial dairy. This research highlights several practical, high-yield protocols for the longevity biohacker:

  • Prioritize Strain Diversity Over Monocultures: Transition away from basic two-strain yogurts to complex, multi-strain fermentations containing at least 8 to 10 distinct synergistic strains, targeting minimum daily doses of 10^10 to 5x10^11 CFU/g.

  • Target the Bacteroides-SCFA Axis: Upregulating Bacteroides uniformis via diverse probiotics and prebiotic substrates maximizes colonic acetate and butyrate production. Butyrate acts as an essential longevity metabolite, fueling colonocytes and suppressing chronic systemic inflammaging.

  • Monitor Systemic Upregulation of Biomarkers: Utilize targeted multi-strain interventions to actively drive down key aging biomarkers like TNF-alpha and IL-6, while boosting endogenous antioxidant defense enzymes, specifically Superoxide Dismutase (SOD) and Catalase (CAT).

  • Optimize Sleep Architecture via Gut Motility: For those experiencing age-related sleep latency or tracking high cortisol levels, improving intestinal transit via the gut-brain axis provides a non-pharmacological pathway to elevate peripheral serotonin and dopamine, lowering sleep induction times naturally.

Source:

#2

Novelty

This study demonstrates that a complex 10-strain probiotic consortium derived from extreme artisanal environments outperforms standard commercial starter cultures by driving a distinct carbohydrate-degrading functional profile in an RCT. Rather than merely altering composition transiently, it upregulated specific glycoside hydrolases (KEGG pathways K05349, K01190, K12373) to create a cross-feeding niche that permanently or semi-permanently altered commensal Bacteroides density. It provides a clear clinical proof-of-concept that oral bacteriotherapy can selectively target specific sub-dimensions of sleep architecture (latency) and systemic inflammation simultaneously

Replicating the recipe

No consumer product is explicitly sold under the retail name “K-10 Consortium Yogurt.” The specific 10-strain blueprint, protected under Chinese Patent No. ZL202211672052.4, is a proprietary industrial designation formulated directly by Junlebao Dairy Group Co., Ltd. as a specialized investigational material for this clinical trial.

However, you can source the foundational proprietary strains through specific commercial channels, or replicate the functional architecture of the consortium using existing consumer alternatives.

1. Commercial Availability of the K-10 Core Strains

Junlebao utilizes the primary high-yield therapeutic strains from the K-10 consortium across their commercial consumer catalog in China:

  • Lactobacillus paracasei N1115 (also classified as Lacticaseibacillus paracasei N1115): This is Junlebao’s flagship, heavily researched patented strain. It serves as the cornerstone of their functional probiotic lines and is commercially distributed in their premium ready-to-eat probiotic powders and specialized functional yogurt lines (such as targeted iterations of their JianChun [简醇] and functional wellness brands).

  • Lactobacillus rhamnosus X253: This regional isolate, derived from artisanal fermentations in Xinjiang, is wholly owned by Junlebao and incorporated into their advanced multi-strain functional dairy formulations.

2. Structural and Functional Equivalents for Biohackers

If you are operating outside of China or looking to replicate the Bacteroides-SCFA cross-feeding axis without access to Junlebao’s proprietary strain bank (the JMCC depository), standard commercial “two-strain” (L. bulgaricus + S. thermophilus) yogurts will not suffice. You must look for products that mirror the specific ecological niches filled by K-10:

Premium Multi-Strain Kefirs (The Closest Ecological Match)

High-grade, traditional consumer kefirs (such as those from Lifeway Elite or artisanal unflavored raw variants) naturally provide an 11-to-12-strain microbial consortium. They match the exact genus-level diversity of the K-10 group by combining:

  • The Fermentative Lactic Backbone: Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris, and Streptococcus thermophilus.

  • The Flavor/Metabolic Drivers: Leuconostoc mesenteroides.

  • The Therapeutic Probiotics: Advanced Lactobacillus species (L. acidophilus, L. rhamnosus, L. paracasei) and Bifidobacterium animalis.

Biohacker Custom Co-Fermentation Protocol

Because the study explicitly details the precise weight-based starter metrics, advanced biohackers can approximate the K-10 dynamic via custom culturing. The study notes that the substrate’s efficacy relies on delivering complex prebiotics alongside probiotics to trigger cross-feeding.

To build an equivalent system, source a commercial multi-strain starter or combine individual raw powders to achieve the necessary strain array:

Microbial Role Target Genus/Strains in K-10 Accessible Consumer Alternative Strains
Primary Starters L. cremoris, L. lactis, S. thermophilus, L. bulgaricus
 Standard multi-strain Heirloom Yogurt or Kefir Starters.
Aromatic/Acidifiers L. diacetylactis, Leuconostoc mesenteroides
 Mesophilic cheese starter cultures (e.g., Flora Danica).
Therapeutic Strains L. rhamnosus X253, B. animalis i797, L. paracasei N1115, L. acidophilus
 High-potency, clean capsule isolates (e.g., L. rhamnosus GG, B. lactis Bi-07, L. paracasei Lpc-37).

Practical Synergy Note: To achieve the systemic down-regulation of TNF-alpha and IL-6 demonstrated in the paper, oral intake must be paired with complex, indigestible carbohydrates (e.g., partially hydrolyzed guar gum, inulin, or beta-glucan). This satisfies the predictive glycoside hydrolase pathways required to expand your native Bacteroides population and drive colonic butyrate synthesis.

#3

The exact strains comprising the K-10 multi-strain consortium, along with their specific depository designations and weight-based proportions as detailed in the paper “1-s2.0-S1756464626002161-main.pdf”, are listed below.

General Taxonomic Composition

The general K-10 bacterial flora consists of the following 10 species and subspecies:

  • Lactococcus lactis subsp. lactis
  • Lactococcus lactis subsp. cremoris
  • Lactococcus lactis subsp. diacetylactis (designated as Lactococcus lactis diacetyl subspecies)
  • Leuconostoc mesenteroides subsp. mesenteroides
  • Streptococcus thermophilus
  • Bifidobacterium lactis (further identified as Bifidobacterium animalis)
  • Lactobacillus acidophilus
  • Lactobacillus paracasei
  • Lactobacillus rhamnosus
  • Lactobacillus delbrueckii subsp. bulgaricus

Exact Strain Designations and Formulations (By Weight)

The precise formulation specified in the materials and methods section utilizes the following designated strains and exact parts by weight:

  • Lactococcus cremoris JMCC0035: 25 to 30 parts
  • Lactococcus lactis jmcc0036: 20 to 30 parts
  • Streptococcus thermophilus jmcc16: 20 to 30 parts
  • Lactobacillus delbrueckii subsp. bulgaricus JMCC0018: 0.5 to 1.5 parts
  • Lactococcus lactis subsp. diacetylactis: 0.01 to 0.15 parts
  • Leuconostoc mesenteroides subsp. mesenteroides: 0.01 to 0.15 parts
  • Lactobacillus rhamnosus x253: 10 to 20 parts
  • Bifidobacterium animalis i797: 5 to 15 parts
  • Lactobacillus paracasei n1115: 1 to 10 parts
  • Lactobacillus acidophilus: 0.1 to 1.5 parts
#4

Sourcing:

Proprietary Sourcing Constraints

The exact bacterial strains used to build the K-10 consortium—specifically Lactococcus cremoris JMCC0035, Lactococcus lactis jmcc0036, Streptococcus thermophilus jmcc16, Lactobacillus delbrueckii subsp. bulgaricus JMCC0018, Lactobacillus rhamnosus x253, Bifidobacterium animalis i797, and Lactobacillus paracasei n1115—are proprietary assets owned exclusively by Junlebao Dairy Group Co., Ltd. (Shijiazhuang, China). They are maintained in a private industrial depository and cannot be purchased directly online as a pre-blended retail product.

To replicate the functional architecture of this 10-species ecosystem, you must source matching species and subspecies equivalents from verified biological repositories or commercial food-science culture houses.

Commercial Dairy and Fermentation Suppliers (The Practical Functional Path)

Sourcing single-species vials from biological repositories is inefficient for functional food applications. Commercial culture houses group these exact subspecies into complex, synergistic starters that can be handled easily.

Dairy Connection

  • Available Blends: Supplies commercial mesophilic and thermophilic cultures that consolidate multiple K-10 subspecies. For example, the Chr. Hansen XPL-1 starter culture contains Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. diacetylactis, Leuconostoc mesenteroides, and Streptococcus thermophilus.

  • Cost: $18.00 – $26.00 per 50-Unit pouch (processes up to 500 liters of liquid base).

  • Direct Link: Dairy Connection Probiotic Cultures Product Page

Cultures for Health

  • Available Blends: Distributes retail-scale multi-strain starters containing the core thermophilic lactic acid backbone (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus) combined with therapeutic additions like Lactobacillus acidophilus and Bifidobacterium species.

  • Cost: $15.00 – $22.00 per multi-pack box.

  • Direct Link: Cultures for Health Yogurt Starter Product Page

3. High-Concentration Consumer Monocultures (The Therapeutic Add-ons)

The final key therapeutic drivers in the K-10 clinical trial—specifically Lactobacillus rhamnosus and Lactobacillus paracasei—must be added at high viability ranges ($1\times10^{10}$ to $5\times10^{11}$ CFU/g) to match the study’s dosing metrics.

Custom Probiotics

  • Available Species: Specializes in high-potency, single-strain bulk probiotic powders free of dairy, sugar, and carriers. They supply pure Lactobacillus rhamnosus and Lactobacillus paracasei isolates.

  • Cost: $65.00 – $110.00 per 50-gram container (verified at 400 billion CFU per gram).

  • Direct Link: Custom Probiotics Single-Strain Powder Line

Critical Implementation Note

While these commercial alternatives match the exact species and subspecies taxonomy of the K-10 clinical trial, they use distinct clonal variations. To maximize the cross-feeding mechanism that recruits native Bacteroides and generates the therapeutic acetate and butyrate levels observed in the study, you must ferment these cultures alongside complex prebiotic fibers like inulin or partial hydrolyzed guar gum.

1 Like